In the past week, breakthrough developments surrounding Ozempic and its use for weight loss have dominated health news, reflecting sweeping changes in both medical access and public perception. According to Popular Mechanics, Novo Nordisk, the pharmaceutical giant behind Ozempic and the similar injectable Wegovy, has just revealed the results of a major 71-week clinical study evaluating an oral pill form of semaglutide, the active ingredient in both Ozempic and Wegovy. This study, published in The New England Journal of Medicine, found that the daily pill achieved nearly the same results as the weekly injection, with participants losing an average of 16.6 percent of their body weight, far surpassing the 2.7 percent weight loss seen in the placebo group. About one third of those taking the pill lost more than 20 percent of their starting weight, signaling not just statistical significance but profound clinical impact. The trial also reported side effects consistent with earlier injectable versions, including increased incidences of nausea and vomiting, though these were not severe enough to derail the optimism surrounding the pill’s future.

Compounding these scientific advancements, the White House this week announced successful negotiations with both Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 receptor agonists—the drug class of Ozempic, Wegovy, and Zepbound—which many insurance providers had previously excluded or charged full price for. Now, eligible patients may see their out-of-pocket costs plummet from over one thousand dollars per month to a much more accessible fifty to three hundred fifty dollars depending on dosage and coverage. According to comments from Kim Fisher at the UC Davis Innovation Institute for Food and Health, these price adjustments are expected to drive a swift increase in demand and medication use, with around one in eight adult Americans having already tried some form of GLP-1 therapy.

Despite the popularity and transformative outcomes touted by both consumers and medical professionals, Ozempic and related drugs are not without controversy. While these medications have reshaped the landscape for obesity and diabetes treatment, as UC Davis reports, emerging evidence indicates a need for caution and individualized care. Some patients experience notable gastrointestinal effects such as nausea and diarrhea, largely because GLP-1 drugs alter how the gut processes food and signal fullness to the brain. In addition, while fat loss can be dramatic, experts highlight that up to one quarter of the total weight lost may be from lean muscle, underscoring the importance of physical activity and adequate protein to preserve strength. Another concern echoed this week involves bone health, as rapid weight loss and restricted nutrition may inadvertently reduce bone density, especially in older adults and postmenopausal women. Leading researchers emphasize that a successful and safe weight loss journey with Ozempic demands precision nutrition, attentive exercise regimens, and regular monitoring to minimize health risks and maximize wellbeing.

The intersection of celebrity culture with the Ozempic phenomenon also drew fresh attention over the past week, especially regarding Oprah Winfrey’s evolving relationship with the drug. Oprah, who has long shared her struggles with weight publicly, admitted in recent interviews that she initially resisted taking Ozempic, saying she felt it was the easy way out and preferred to focus on lifestyle change. According to AOL, she reflected on her internal conflict about using medical intervention for weight loss, underscoring how the rise of drugs like Ozempic has forced a cultural reckoning over what constitutes effort, discipline, and legitimacy in personal health. While some celebrity peers openly dismiss rumors or deny any use of weight loss drugs, Oprah’s decision to speak candidly about her hesitation and subsequent...

Ozempic continues to spark headlines as its role in weight loss becomes more central to discussion in both medical circles and popular culture over the past week. Driven by ongoing demand and complex debate, the medication, originally developed for managing type two diabetes, is being increasingly prescribed as an aid for weight reduction. Recent news coverage demonstrates that the public conversation about Ozempic’s impact is not slowing down. One of the most prominent voices weighing in this week has been Oprah Winfrey, who has offered candid reflections on her own experiences with Ozempic and the accompanying social reactions.

This week, Oprah Winfrey openly addressed her use of Ozempic, stating that the medication had been part of her recent weight loss journey. The disclosure provoked a surge of reaction, with many in the media and public responding to her admission. According to JB Press, Oprah was direct in acknowledging how Ozempic had contributed to her results and sincerely discussed the reasons behind her choice. She emphasized that her decision was informed not just by the desire for weight loss, but by a broader understanding of health, aging, and the pressures faced by individuals in the public eye. Oprah expressed that Ozempic helped her manage not only her physical appearance but also her relationship with food and ongoing health challenges.

The admission generated considerable controversy, especially in social media circles and news outlets. AOL reports that Oprah faced criticism from some who accused her of taking what they described as the easy way out. Detractors argued that reliance on medication sidesteps the harder emotional and behavioral work of traditional weight loss approaches. Yet, others pointed out that access to new treatments like Ozempic can democratize health outcomes for people who have battled obesity and associated health issues for years. Notably, Oprah addressed the backlash with clarity, stating that individual health decisions are complex and personal, and that stigma can deter meaningful progress in addressing obesity.

While much of the discussion this week has centered on celebrity use and cultural debate, medical professionals have continued to caution that Ozempic is not a substitute for healthy eating or exercise. They underscore that while it may curb appetite and support weight loss, it should be prescribed thoughtfully and monitored by a physician. New data has emerged suggesting that demand for Ozempic has increased during the past seven days, especially following endorsements by well-known personalities. This has prompted ongoing examination regarding accessibility, cost, and responsible use.

The increased attention on Ozempic this week has also reignited questions about the long-term effects of its use. Medical experts, as quoted in several news sources, remind listeners that Ozempic is primarily intended for people with type two diabetes, and that off-label use must be scrutinized to prevent negative outcomes. They warn against seeking the medication without proper guidance and note that lifestyle change remains a crucial part of sustainable weight management. The FDA continues to evaluate the safety profile of these drugs as more data comes to light.

Overall, the recent wave of coverage shows that Ozempic is at the heart of a rapidly evolving public conversation about medicine, body image, and social stigma. Oprah Winfrey’s openness this week has made a significant impact, both in encouraging honest dialogue and in prompting critical reflection about how we perceive health and beauty in the modern era. The question of whether medical intervention for weight loss constitutes an easy fix or an important tool remains active, and the story continues to evolve as more individuals and experts join the discussion.

Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet...

Recent research has revealed that the heart health benefits of the weight loss drug Ozempic, which contains the active ingredient semaglutide, are not solely due to weight loss. A large study published in The Lancet and led by researchers at University College London analyzed data from more than seventeen thousand adults aged forty five and older who were overweight and had cardiovascular disease. The participants were randomly assigned to receive weekly injections of semaglutide or a placebo. The study found that semaglutide significantly reduced the risk of major cardiac events such as heart attacks, strokes, and cardiovascular deaths, regardless of how much weight each participant lost during the first four and a half months of treatment. This means that even people who lost little or no weight experienced similar heart protection as those who lost a substantial amount.

The study also looked at the impact of waist circumference, which is a marker for visceral fat, and found that a reduction in waist size was linked to about one third of the heart benefits seen in patients taking semaglutide. However, the majority of the cardiovascular benefit was not explained by changes in weight or waist size alone. This suggests that semaglutide may have direct effects on the underlying causes of heart disease, beyond just helping people lose weight. Experts say this could mean the drug might be beneficial for patients who are not severely overweight, including those with BMIs in the normal range, although further research is needed to confirm this.

Oprah Winfrey has recently spoken about her own experience with Ozempic, describing it as a tool she uses to manage her weight. She has emphasized that medication is not the only way to lose weight and that it should be seen as one option among many. Oprah has also discussed the broader cultural conversation around weight loss drugs, highlighting the need to address weight stigma and body shaming. Her openness has sparked a national dialogue about the role of prescription medications in weight management and the importance of focusing on overall health rather than just appearance.

The findings from the latest research are prompting doctors and researchers to reconsider how they approach the treatment of obesity and heart disease. While Ozempic and similar drugs were originally developed for diabetes, their ability to protect the heart even without significant weight loss is a major development. This could lead to new treatment strategies for people at high risk of cardiovascular events, regardless of their body size. As the medical community continues to explore the full range of benefits and risks associated with these medications, the conversation around weight loss and heart health is becoming more nuanced and inclusive.

Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

In the past week, Ozempic and its role in weight loss have remained at the forefront of health news as public discussion deepens about its efficacy, risks, and the pronounced cultural shift these medications have sparked. Ozempic, known generically as semaglutide and originally developed as a diabetes treatment, is a GLP-1 receptor agonist that works by slowing gastric emptying and suppressing appetite, making users feel full longer and reducing overall food intake. This mechanism has made it exceptionally popular for weight loss, particularly as social media, celebrity testimonials, and off-label prescribing converged to push demand higher than ever before. Market analysts note that by late 2025, the majority of new Ozempic prescriptions are for weight management rather than diabetes, marking a significant departure from its intended clinical use and raising concerns about access for patients with diabetes who genuinely need the drug.

The transformation of Ozempic from a type two diabetes solution to a cultural touchstone for cosmetic weight loss is partly credited to the attention from high-profile figures such as Oprah Winfrey. This week, Oprah appeared at the American Ballet Theatre Fall Gala in New York City, her appearance turning heads and fueling conversation due to her notably slimmed-down figure. Reports from Hello Magazine describe Oprah’s confidence on the red carpet as she showcased a dramatic weight loss of more than fifty pounds, achieved through a combination of lifestyle modifications and, crucially, the assistance of a GLP-1 medication. At age seventy-one, Oprah has spoken openly this week about the lifelong struggle with her weight and the social stigma that accompanied it. She told People Magazine that after decades of blame and shame, both from external commentators and herself, the availability of medically approved weight loss medications feels to her like both relief and redemption. She described how the weight loss journey for her began in earnest following knee surgery in 2021, when she started an active regimen of hiking and physical fitness, complemented eventually by her doctor’s prescription for semaglutide.

Oprah acknowledged grappling with the stigma tied to weight loss medications, initially resisting the idea out of concern it may appear she was taking an easy way out. However, recent interviews reveal she has set aside any feelings of shame, now describing the medication as a legitimate tool—one that enabled her to shed long-standing weight and maintain her health, not just for cosmetic reasons but as a genuine medical necessity. Though some have criticized the trend of using medications such as Ozempic, Wegovy, and Mounjaro for cosmetic weight management, Oprah’s insights over the week have reframed the conversation for many listeners. She emphasized that the ability to access medication for weight issues in her lifetime is not something to hide but a breakthrough for many who have suffered physically and emotionally from long-term obesity and its attendant health risks.

The clinical conversation around Ozempic has also intensified this week. Drug safety concerns, including the risk of gastrointestinal complications such as pancreatitis and gastroparesis, have been spotlighted by healthcare outlets and legal analysts. Regulatory agencies continue to grapple with the surge in off-label use among populations that may not fully meet the criteria for medical obesity, often motivated by the relentless demands of modern aesthetics rather than underlying health needs. Medical professionals report increasing pressure from patients desperate to access these drugs after seeing dramatic transformations online, which has complicated the careful balancing act between ensuring proper care and responding to unprecedented demand.

Critically, the public discourse, amplified by Oprah’s willingness to openly discuss her experience, is moving the conversation from...

In the week’s most talked about health news, Ozempic remains front and center as both a weight loss therapy and a social phenomenon. The drug, whose medical name is semaglutide, has been generating headlines after a landmark study published in the October 2025 issue of Value in Health found that broader Medicare access to Ozempic could lead to significant cost savings for the health system alongside notable medical benefits. Researchers from the University of Washington and their collaborators projected that covering Ozempic for conditions like diabetes, overweight and obesity, and liver disease would reduce the risk of life-changing complications such as heart attacks, chronic kidney disease, and sleep apnea. Their model suggested Medicare would save hundreds of millions of dollars over the next decade while thousands of patients would avoid cardiovascular events, serious kidney problems, and even deaths thanks to expanded Ozempic use.

This new data reignited debates about the ethics and economics of prescription weight loss. McGill University experts highlighted that semaglutide and similar GLP-1 receptor agonists are being investigated beyond obesity and diabetes, with potential roles in treating heart failure, fatty liver disease, sleep disorders, and even certain addictions. However, physicians warn listeners about unresolved safety concerns, such as the risk of gallbladder issues and possible psychiatric side effects over extended periods. With millions now seeking a prescription, public health leaders are also calling attention to cost and access barriers especially as high demand pressures insurance systems and out-of-pocket costs remain significant for many patients.

Part of Ozempic’s pop culture appeal comes from celebrity testimonials, and no one drives the conversation more than Oprah Winfrey. According to AOL and recent lifestyle coverage, Oprah shocked fans this week with a fresh social media post revealing her dramatic weight loss while openly sharing that Ozempic is part of her approach. Still, she repeatedly emphasizes that medication is only one aspect of her journey. Her message to listeners is clear: The true transformation did not come from a miracle drug, a crash diet, or punishing exercise, but rather a holistic overhaul fueled by compassion and science. Oprah describes her regimen as balancing whole foods, like fruits and vegetables, with enjoyable activity and never forceful deprivation. Most importantly, she rejects years of shame and self-blame, framing obesity as a medical condition rather than a moral failing. Oprah’s transparency about using prescription weight loss medication, though not naming Ozempic directly, is credited for helping normalize the conversation and encouraging others to view medical therapies as valid tools for improving health when used responsibly.

Blog reports and interviews highlight that Oprah’s prescription is supervised and supports her broader health plan, including dietary changes and regular movement. Oprah states that Ozempic quiets the “food noise” in her brain, giving her room to make healthier choices without feeling tormented by cravings. She adamantly denies that the shot is any kind of “easy way out,” framing it instead as a supportive measure that allows other healthy habits to flourish. This week, several outlets repeated Oprah’s warning to avoid quick-fix thinking: She tells followers that lasting weight loss is about self-compassion, consistency, and letting go of guilt. The wave of support for her message underscores a shifting cultural view of weight loss drugs; they are increasingly seen as medically legitimate, though experts urge listeners not to rely solely on medication and to view it as part of a larger toolkit.

One persistent problem is misleading online marketing, with scam trackers and consumer advocates warning this week about fraudulent social media claims linking Oprah to unapproved products. The...

Ozempic remains at the center of American conversations around weight loss, especially as the demand for prescription medications aimed at shedding pounds continues to surge nationwide. This past week, two topics have dominated news coverage. First, the ongoing popularity and the urgent warnings about counterfeit versions of weight loss drugs like Ozempic. Second, the role that Oprah Winfrey’s public statements are playing in influencing perceptions about what these medications can—and cannot—actually do.

According to ABC News, federal officials are sounding the alarm as more patients turn to online sellers for Ozempic and similar drugs, leading to what Homeland Security calls an “absolutely” unprecedented surge in dangerous counterfeits. Many of these illegal sellers use phrases like “No Rx” to bypass regulations, promising weight loss drugs without prescriptions or safety guarantees. The Food and Drug Administration clarifies that Ozempic, Wegovy, and Mounjaro are tightly regulated, manufactured under strict scrutiny, and are only legal with a prescription. In contrast, unofficial versions dubbed “Fauxzempic” can be counterfeit and potentially life-threatening. Recent coverage stresses that anyone seeking true Ozempic should rely solely on licensed medical professionals and FDA-approved pharmacies to avoid potentially severe health risks.

This swell in demand for ozempic and its lookalikes comes as people report dramatic results. Yet, the landscape is muddied not just by fake medicines but also by fraudulent endorsements using celebrity imagery and artificial intelligence. WCPO reports this week on how scammers are exploiting advanced technology to create deepfake videos of Oprah Winfrey allegedly promoting various supplements that claim to mimic Ozempic’s effects. These deceptive ads have tricked some consumers into spending hundreds of dollars on unknown substances shipped with no instructions and no scientific backing. Both the Better Business Bureau and independent investigative reports confirm Oprah Winfrey has repeatedly stated she does not endorse any over-the-counter supplement or nonprescription product for weight loss. Deepfake technology now allows scammers to fabricate realistic celebrity recommendations, making it increasingly difficult for ordinary people to separate truth from fiction.

Oprah’s real stance on Ozempic and weight loss has been thoughtfully discussed in recent interviews and podcasts. On a Yale University obesity medicine episode of The Oprah Podcast, Oprah explained she had long believed thinness was purely a matter of willpower. That changed when she used a prescription GLP-1 medication herself. Oprah described how she finally understood that for many, including herself, the battle with weight is between biology and behavior. She spoke of “food noise”—the constant thoughts and cravings that affect those struggling with obesity—and admitted that, even with medication, this noise never truly disappears. She emphasized medications like Ozempic are not magic bullets, pointing out that any sustainable weight loss for her requires exercise, vigilance, and ongoing lifestyle changes. In her own words published by People and reiterated in current reports, Oprah acknowledged relief and “redemption” in having medical tools to manage her health after decades of blame and shame but firmly denies these medications should be seen as effortless solutions.

Simultaneously, current research is highlighting new and unusual side effects associated with using Ozempic and similar drugs, especially in medical imaging. The Independent this week shared findings that patients who use these medications and then undergo PET scans might experience “hot spots” during imaging, potentially complicating diagnostic procedures for certain conditions. This development underscores the importance of informing healthcare providers about any recent prescriptions for GLP-1 drugs, so they...

Ozempic, a once little-known diabetes medication, has dominated health news this week as its widespread use for weight loss continues to reshape conversations and access in the United States. Most recently, major headlines have focused on Costco’s move to make Ozempic and its cousin Wegovy available to members at a significant discount. According to CBS News, as of this week, Costco, in partnership with drugmaker Novo Nordisk, is now selling a one-month supply of Ozempic or Wegovy for four hundred ninety nine dollars, which is about half the typical out-of-pocket cost for many. To purchase either medication, a valid prescription remains necessary. This partnership signals not just mainstream acceptance but also an effort to address steep costs and offer greater accessibility for adults seeking weight loss options.

The surge in demand for Ozempic and similar drugs stems from their unique biological mechanism. These medications, known as GLP-1 agonists, reduce blood sugar levels and slow digestion, which leads to increased feelings of fullness and decreases appetite. Over the past two years, they have become household names for people aiming to lose considerable weight, especially as insurance companies and retail pharmacies try to keep up with consumer interest. However, it is important to recognize that not all patient experiences are alike, as some doctors continue to prescribe these medications off-label, taking into account underlying health conditions like high blood pressure, type two diabetes, or a family history of obesity.

This discussion has garnered even more attention with public figures sharing their own stories. Oprah Winfrey, in particular, remains at the forefront of this cultural conversation. In several recent interviews, including a piece published by People and other press appearances this past week, Oprah reiterated her nuanced stance on weight loss medication. After decades of enduring public scrutiny and shaming related to her weight, Winfrey disclosed that she began using a doctor-prescribed GLP-1 medication to manage fluctuations in her weight. She described this experience as a great relief, specifically highlighting the shift in attitude toward medical intervention versus longstanding willpower-based or diet-centric approaches. In Oprah’s words, the medication has become one of several tools she uses to avoid cycles of extreme loss and regain. However, she firmly rejects the notion that medication alone is a magic bullet. She continues to emphasize the need for a holistic approach—regular exercise, protein-focused nutrition, and ongoing self-acceptance all play critical roles in her routine.

Oprah’s reflections also acknowledge the persistent stigma surrounding weight and the cultural biases faced by millions. She has spoken candidly about her sense of urgency to live well as she ages, as well as her personal journey to let go of blame and shame. This week, in response to both supporters and critics, Oprah made it clear that the goal should be to foster choice and acceptance for anyone dealing with weight-related challenges, encouraging conversations rooted in empathy and factual medical understanding. She is adamant that prescription drugs like Ozempic are not a quick fix but rather a supportive tool within a broader context of well-being.

Beyond celebrity narratives, news coverage describes the wider societal impacts of increased Ozempic availability. For many adults, easier access through discount programs and national chains like Costco means a chance to address health issues once thought to be intractable. At the same time, doctors urge caution; medical professionals stress that each patient should consult their provider to weigh risks, benefits, and long-term lifestyle adjustments. As this story evolves, questions about insurance, stigma, and the future of chronic weight management remain front and center, with new policies likely to emerge as...

Ozempic continues to dominate headlines as one of the most discussed weight loss medications of the past year and now, new developments are changing how much access Americans have to these drugs. As of this week, Costco has entered into a partnership with Novo Nordisk, the company that manufactures Ozempic and Wegovy, and is now offering both medications at a significant discount for its members who already have a prescription. According to CBS News, starting this week, Costco members can purchase a one month supply of Ozempic or Wegovy for four hundred ninety nine dollars, which is roughly half of what many people have been paying out of pocket previously. This move is expected to have a huge impact on not just how patients access the drug, but how future pricing structures for weight loss treatments may evolve as more major retailers get involved. The discounted prices also highlight the high demand and growing normalization of medically managed weight loss, often led by medications called GLP one receptor agonists, including Ozempic.
Alongside this major retail story, legal and medical conversations around Ozempic continue to evolve rapidly. Recent updates to ongoing lawsuits focus on the potential side effects, particularly rare but significant risks such as gastroparesis, which is a condition where the stomach muscles slow down and make digestion difficult, and a rare eye disorder called non arteritic anterior ischemic optic neuropathy, which can result in sudden vision loss. Law firm updates indicate that, as the number of suits rises, the burden falls on plaintiffs to prove that their injuries were directly caused by medications like Ozempic instead of underlying health conditions. Regulatory agencies both in the United States and Europe have responded by requiring more robust disclosures about these risks, including ordering updated warning labels to reflect new evidence about potential for vision problems. Despite these risks, the drugs continue to be approved for new uses. For example, the FDA recently granted a new approval for Wegovy, a higher dose formulation of semaglutide, to treat a type of fatty liver disease, demonstrating ongoing confidence in the benefits of GLP one medications in metabolic and chronic disease management, even as side effect warnings grow more prominent.
No discussion of weight loss in America can be complete without mention of Oprah Winfrey, whose personal journey and recent comments have again become part of the national conversation. Last year, Oprah publicly shared for the first time that she was using a doctor prescribed weight loss medication as part of her health plan, calling the experience a relief after years of struggling with public scrutiny and self blame over her weight. While she has chosen not to name the specific drug, Oprah told People Magazine and her followers that the new generation of weight loss medications has given her permission to let go of shame and take a more holistic approach to health. Oprah has been clear in stating that medication is not a miracle solution by itself. She insists that long term success still depends on regular exercise, mindful eating, and overall lifestyle changes. She has said that she uses the medication as a tool to avoid the cycle of weight loss and regain that she and many others have experienced. In her own words, the existence of a medically approved prescription brings relief, redemption, and a sense that she no longer needs to hide or feel shame. She has called for more compassion toward those living in larger bodies and wants to move the conversation away from blame, both personal and societal.
All of these recent developments show just how quickly the field of weight loss medications is shifting, marked by expanding retail access, new regulatory scrutiny, and evolving attitudes about health and personal responsibility. As Americans weigh their choices, it is clear this story will continue to be front and center...

Ozempic, a widely discussed prescription medication originally intended for treating type two diabetes, has dominated conversations about weight loss in both the medical and celebrity worlds this week. The medication, whose active ingredient is called semaglutide, has become a cultural phenomenon for its ability to induce significant weight loss, owing to its appetite-suppressing effects and how it slows down the digestive system. Though it received United States Food and Drug Administration approval for diabetes in 2017, its popularity soared when doctors and patients began observing remarkable weight loss results. Now, celebrity usage has become a major talking point, with Hollywood stars and public figures openly discussing their experiences. According to an article in AOL News, experts suggest that a large number of A-listers have turned to Ozempic, with some physicians confirming that Hollywood clients are now hosting informal gatherings where people are introduced to the drug by specialty nurse prescribers and encouraged to seek prescriptions. Events like the Golden Globes have even been called Ozempic's biggest night by some hosts, who have noted the visible transformation in many attendees’ figures.

The impact of this trend is reflected in the way sizes have shifted in public appearances, with Beverly Hills plastic surgeons estimating that stars who were once a size six or eight are now as small as zero or two. Yet, doctors are expressing concern about the potential side effects of this new wave of usage. Dr Michael Hakimi, a plastic surgeon, explained to Page Six that beyond just the shrinking figures, there is a growing demand for surgical intervention to remedy side effects like loose skin and other complications related to rapid weight loss. Another crucial point raised this week is the growing number of celebrities who, though thin already, are using small doses to maintain their size, since Ozempic suppresses appetite to the point that users sometimes no longer feel hungry.

Oprah Winfrey remains central to the Ozempic and weight loss narrative, given her continual public discussion around her body image and health journey. According to IOL and The Independent, Oprah this week spoke candidly on her podcast about her use of GLP one medications like Ozempic, describing it as a relief after a lifetime of struggling with her weight. She explained that the shift to considering medically supported solutions came only after years of battling stigma and shame. Oprah stated that she had come to accept that her struggles were not just about willpower, especially after hosting a major panel last year on the science of obesity and weight management. She said she now uses her medication as a tool and credits it for helping her avoid the cycle of regaining lost weight. However, she emphasized that medication is not a magic bullet and that sustainable results require continued attention to exercise and healthy habits. Oprah told People magazine that she felt a sense of freedom in finally accessing a tool to support her health goals and expressed frustration with the shaming she has experienced, both externally and internally.

The discussions Oprah has fueled intersect with more serious medical news as lawsuits continue to mount against the makers of Ozempic. According to the King Law firm’s update this September, over 2,100 lawsuits are currently pending in federal court. Many of these cases involve severe alleged side effects such as gastroparesis, or paralysis of the stomach, intestinal blockages, and in rarer cases, blindness and hair loss. A study published in August found that hair loss appeared at significantly higher rates for women taking the drug, with some men also affected. The increase in litigation is being watched closely as patients and healthcare professionals weigh the potential risks against the promise of dramatic weight loss and easier diabetes management.
Show more...